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ABSTRACT 
 
Phosphorylation of short linear peptide motifs is a widespread process for the dynamic regulation of 
protein-protein interactions. However, the global impact of phosphorylation events on the protein-
protein interactome is rarely addressed. The disordered C-terminal tail of ribosomal S6 kinase 1 
(RSK1) binds to PDZ domain-containing scaffold proteins, and it harbors a phosphorylatable PDZ 
binding motif (PBM) responsive to epidermal growth factor (EGF) stimulation. Here, we examined 
binding of two versions of the RSK1 PBM, either phosphorylated or unphosphorylated at position -
3, to almost all (95%) of the 266 PDZ domains of the human proteome. PBM phosphorylation 
dramatically altered the PDZ domain-binding landscape of RSK1, by strengthening or weakening 
numerous interactions to various degrees. The RSK-PDZome interactome analyzed in this study 
reveals how linear motif-based phospho-switches convey stimulus-dependent changes in the context 
of related network components. 
 
BACKGROUND 
 
Protein-protein interactions form a functional network, the interactome, which can be dynamically 
regulated by the phosphorylation of network components on disordered protein regions [1].  These 
so-called linear motifs most often bind to structured domains, such as (PSD95/DLG1/ZO-1) PDZ 
domains. PDZ domains belong to one of the most common families of globular domains, with 266 
members in the human proteome [2]. They recognize short linear motifs called PDZ-binding motifs 
(PBMs) at the extreme C-terminus of their target proteins (canonical PBMs) or within internal 
regions (non-canonical PBMs). Canonical PBMs systematically contain a hydrophobic residue 
(most frequently Val or Leu) at their C-terminus (numbered as position 0) and are classified in three 
main classes based on the residue at position -2 (Ser/Thr in the most common class 1, hydrophobic 
in class 2 and acidic in class 3) [3]. In principle, the general consensus sequence determining a 
PBM allows the presence of potentially phosphorylatable residues at any positions except the 
hydrophobic C-terminal position [4]. 
 
PDZ-PBM interactions are involved in various cellular processes and are especially common in 
intracellular signaling pathways. For example, all isoforms of the ribosomal S6 kinase (RSK) of the 
MAPK pathway contain a functional class 1 PBM [5]. RSK has an emerging role in multiple cancer 
types such as glioblastoma or melanoma [6] [7]. Upon mitogenic stimulation, a series of 
phosphorylation events leads to the activation of the MAP kinase ERK1/2 [8]. RSK is one of the 
strongest interaction partners of ERK (compared to other docking motif facilitated MAPK 
interactions) and its complex activation mechanism is also initiated by ERK phosphorylation 
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(Figure 1A) [9] [10] [11]. The C-terminal tail of RSK is a multifunctional linear motif as it contains 
partially overlapping binding sites for ERK, S100B, a tyrosine kinase, phosphatase(s) and PDZ 
domains [12] [13] [14]. Additionally, activated RSK will autophosphorylate its own PBM within its 
intrinsically disordered tail, which will probably affect all of these interactions [15].The RSK1 
PBM contains three potential autophosphorylation sites, while other isoforms contain only two 
(Figure 1B). Among these, Ser732 is found at the -3 position [16] [17]. Thomas et al. observed no 
change with RSK1/2 phosphomimics (at -3) in their interaction with MAGI1, SHANK1 or GRIP1, 
and they suggested that both inactive and active RSKs likely bind to PDZ domain proteins [5]. 
Similarly, our recent work showed that phosphorylation of RSK1 only mildly changed the 
interaction with MAGI1 [15]. In contrast, a recent publication revealed that the phosphorylation (or 
a phosphomimetic mutation) at the analogous site triggered the association between RSK1/3 and the 
PDZ domain of SCRIBBLE and abolished the interaction between RSK3 and the PDZ domain of 
SHANK1 [18]. These results indicated that RSK activation might induce a complex reshuffling of 
its PDZ domain mediated interactome. 
 
In order to elucidate the impact of phosphorylation of a given PBM, binding to all of its putative 
partners in the human proteome needs to be measured, quantitatively. In addition, in vitro observed 
changes need to be validated in cell-based assays. To address these challenges, we applied here a 
recently developed high-throughput approach [19] to measure the individual binding affinities of 
the 266 known human PDZ domains for both the unphosphorylated and phosphorylated RSK1 
PBMs. Furthermore, we used luciferase complementation assay to measure the effect of EGF 
stimulation on full-length RSK-PDZ interactions in HEK293T cells. Our work reveals new kinase-
scaffold complexes, the mechanism of PDZ domain-based RSK substrate targeting, and identifies 
new functions of RSK1. 
 
RESULTS 
 
PDZome-binding profiles of native and phosphorylated RSK1 PBMs 
 
To investigate how phosphorylation can modulate the binding of the RSK1 PBM to PDZ domains, 
we used the automated high-throughput holdup assay, which allows to measure binding intensities 
(BIs) for a large number of domain-motif pairs. As compared to the original work describing this 
approach [19], we used an updated version of our PDZ library, including all the 266 known human 
PDZ domains [20]. We were able to quantify the interaction of 255 PDZ for the unphosphorylated 
RSK1 peptide and 252 for the phosphorylated form (96% and 95% of the human PDZome, 
respectively). Both datasets were plotted in the form of "PDZome-binding profiles" (Figure 2A) 
representing all the individual BIs measured for each PDZ domain for the unphosphorylated and 
phosphorylated RSK peptides, respectively. Using BI = 0.2 as the minimal threshold for a 
significant PDZ-peptide interaction, the holdup assay identified 34 potential RSK1 binders, 
including 26 PDZ binders for the unphosphorylated peptide and 25 binders for the phospho-peptide 
(Figure 2A, S1, Table S1). The general distribution of the PDZome-binding profiles was similar in 
both cases. However, phosphorylation decreased the maximal and average BIs from 0.77 to 0.54, 
and from 0.42 to 0.33, respectively. Furthermore, the order of the PDZ domains that bind best to the 
unphosphorylated and phosphorylated RSK1 PBM was markedly different, as visually illustrated by 
the global reshuffling of their respective profiles (Figure 2A). Using the same threshold for 
significant binding, the phosphorylated RSK1 PBM lost 12 of the detectable binders and gained 10 
new binders as compared to the unphosphorylated peptide. This implies that at least 35% of the 
potential binders interact (often with variable affinities) to both phosphorylated and native RSK1 
peptides while the rest of them binds detectably to only one state of the RSK1 PBM. 
 
In vitro validation of PDZ-RSK interactions by biophysical approaches 
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To validate the results of the holdup assay, we used orthogonal in vitro approaches: isothermal 
titration calorimetry (ITC), surface plasmon resonance (SPR-Biacore), direct and competitive 
fluorescence polarization (FP) (Table 1 and Figure S2, S3). To benchmark the BIs of the holdup 
assay against steady-state dissociation constants, we decided to systematically test by high-
throughput techniques (SPR-Biacore and competitive FP) those interactions that showed a BI value 
larger than 0.4 in any of the two holdup assays (Table 1 and Figures S2, S3). With these methods, 
we were able to accurately measure binding constants of 15 and 28 PDZ-PBM pairs, respectively. 
These experiments quantitatively confirmed the phosphorylation-induced changes in binding 
affinities, which were originally detected by the holdup assay. For example, a 3-6 µM dissociation 
constant was apparent between the PDZ of ARHGEF12 and the native RSK1 peptide, while no 
interaction could be detected with the phosphorylated state. Vica versa, the PDZ domain of 
SYNJ2BP interacted with the phosphorylated peptide with a 10-20 µM dissociation constant, while 
no interaction was detectable with the native state. 
 
We used these datasets to estimate the quantitative correlation between measured BIs and the 
dissociation constants using Monte Carlo modeling and a general equation of the dissociation 
constant. While different experimental methods resulted slightly different affinities (where only two 
Kd pairs showed larger than a magnitude difference), their independent fits resulted similar 
conclusions. We have found that the peptide concentration in the holdup assays was between 14 and 
23 µM (Figure 2B, Table 1). Using this fitted parameter, it can be calculated that the holdup assay 
was capable of detecting any interaction with Kd < 65 µM (at the 0.2 BI cutoff). 
 
Dynamic rearrangement of the RSK1-PDZ interactome in vitro 
 
The holdup assay identified ARHGEF12 as the strongest interaction partner of the 
unphosphorylated peptide (BI = 0.77; KD ≈ 4 µM) (Figure 3 and Table 1, Table S1). This protein is 
a RhoA GEF. It has recently been reported that its interaction with RSK2 is essential in RhoA 
activation and that this interaction leads to increased cell motility in the U87MG glioblastoma cell 
line [21]. We also identified strong interaction with MAST2, which is an AGC kinase similarly to 
RSK (BI = 0.74; KD ≈ 5 µM) [22]. The previously characterized interaction between MAGI1 and 
RSK1 was found among the top binders of the unphosphorylated dataset (BI = 0.43; KD ≈ 20 µM). 
Interestingly, our approach shows that phosphorylation down regulate this interaction by a factor of 
five in contrast to earlier works [5] [15]. This is very likely due to the limited dynamic change of 
other methods (such as ITC) in cases of very weak interactions (for example, compare Figure S3B 
with S3B or S2). The strongest interaction partners of the phosphorylated PBM were three signal 
transducing adaptor proteins SYNJ2BP, SNTA1 and the E3 ubiquitin ligase PDZRN4 (in all cases 
BI ≈ 0.54; KD ≈ 13 µM) (Figure 3 and Table 1, Table S1). 
 
Approximately one third of the identified PDZ interaction partners of RSK1 were capable to 
interact with both states of the PBM (Figure 3B). By using the holdup assay we had the unique 
opportunity to gain quantitative insight into the dynamic changes that occur after a single 
phosphorylation event (Figure 3C). At the two extremes, RSK1 was engaged in OFF and ON 
"phospho-switches" (according to our detection threshold) with ARHGEF12 and SNX27, 
respectively. All other interactions showed a gradual modulation by phosphorylation. In conclusion, 
we provided in vitro experimental evidence that phosphorylation reshuffles the whole RSK1-PDZ 
interactome. 
 
The dynamics of RSK1-PDZ interactions in cells 
 
The observed changes in steady-state binding affinities suggested large-scale rewiring of the RSK-
PDZ interactions. To test this concept, we validated selected interactions in a cellular context using 
a split-luciferase fragment complementation system, called NanoBiT. This method is appropriate 
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for detecting dynamic changes in PPIs [23]. Instead of using isolated, purified PDZ domains and 
RSK peptides, we used full-length proteins in HEK293T cells. Wild type (WT) and two mutant 
versions of RSK1 were used. The L714E mutation eliminates the interaction between ERK and 
RSK, therefore RSK cannot be activated [9]. The ΔC1 truncation eliminates the last residue of 
RSK1 and thus suppresses the functional PBM of the protein [15]. We obtained high luminescence 
signals with the ARHGEF12, GOPC, PARD3B, MAGI1 and SYNJ2BP sensors in serum-starved 
cells (Figure 4A). The C-terminal truncation significantly reduced the luminescent signal in all 
cases, while the L714E mutation decreased the luminescence outputs for PARD3B and SYNJ2BP. 
 
EGF stimulation can be used to turn on the ERK signaling cascade, RSK activation and its PBM 
autophosphorylation [24]. Extracellular stimulation induced changes in NanoBiT sensor brightness 
within the same timescale as ERK-RSK dissociation (Figure 4B). In all cases, the maximum change 
was detectable between 10-20 min and the signal started to disappear after 30-45 min. As in our 
previous study [15], we observed periodic signals, which seem to be a characteristic feature of 
RSK-based interactions. ARHGEF12, GOPC and MAGI1 showed a decrease in luminescence after 
stimulation. In contrast to these OFF signals, PARD3B did not show any change after activation of 
the pathway, while SYNJ2BP showed an increased luminescence after EGF stimulus. Results of 
this cell-based PPI tests showed a good agreement with in vitro measurements. 
 
A compendium of potential RSK targets 
 
Our high-throughput study identified a wealth of novel RSK-binding PDZ domains. The proteins 
that contain these RSK-binding PDZ domains represent in principle, candidate substrates of RSK 
kinases. In previous studies, only a few PDZ-containing partners of RSKs were assumed to be 
substrates [5] [15] [25]. To investigate this issue, we collected RSK-focused phosphoproteomic 
datasets for a meta-analysis. To our knowledge, there are three such datasets. (i) Galan et al. 
searched for RSK substrates using specific inhibitors [26]. (ii) Moritz et al. tried to find tyrosine 
kinase activated AGC kinase substrates [27]. (iii) Avey et al. used the viral ORF45 protein to 
activate the ERK-RSK axis in cells and they searched for up- or down-regulated phosphoproteins 
[28]. (iv) In addition, a compendium of ERK targets has recently been published [29]. It is a 
systematic collection of ERK related phosphoproteomic studies containing both direct and indirect 
ERK substrates. The compendium is also a valuable resource for potential RSK phosphosites 
(Rxx[ST] and RxRxx[ST] motifs) [26]. The compendium contains 1477 [ST]P sites (from 892 
proteins), 544 Rxx[ST] sites (from 430 proteins) and 458 other phosphorylation sites (from 330 
proteins). We used this Rxx[ST] subset of the ERK compendium as an additional resource to our 
meta-analysis. The four potential RSK substrate collection, termed here as RSK compendium, 
included 997 potential substrates, where 349 substrates were identified in more than one study 
(Figure 5A, Table S2). Only 35 substrates were identified in all four phosphoproteomic datasets, 
including some well characterized RSK substrates, such as ARHGEF12, EIF4B, EphA2, GSK3B, 
PFKFB2, PPP1R12A (MYPT1), RPS6, or SLC9A1 (NHE1) [21] [30] [31] [32] [33] [34] [35]. 
 
Direct and indirect phosphorylation by ERK and RSK 
 
Of the potential RSK substrates, discussed above, only 28 were PDZ-containing proteins, about half 
of which were identified only in a single dataset (Figure 5B). Only four direct RSK1 binders were 
identified in both the RSK compendium and in our holdup assay: ARHGEF11 and 12, MAST2 and 
SHROOM2. Notably, ARHGEF12 was identified in all phosphoproteomic datasets as a PDZ-
containing RSK substrate and was also the strongest binder of the unphosphorylated RSK1 peptide 
in the holdup assay. Additionally, we have also found three additional partners (GRIP, SCRIB, 
NHERF1) binding to other RSK isoforms [18] [5] [25]. Conversely, it is worth noting that many of 
the strong RSK1 PBM binders (like GRID2IP, GOPC, PDZD7 or PDZRN4) do not contain any 
phosphorylation site matching the RSK1 consensus motif [16]. 
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The RSK and the ERK compendiums show an overlap, indicating that some substrates can be 
phosphorylated by both RSK and ERK (Figure 5AB). Although the MAPK- and the PDZ-binding 
motifs are found in the same C-terminal tail region of RSK where they are only separated by a few 
residues, it is stereochemically possible to form a ternary complex between the three domains [15]. 
Therefore, ERK can also phosphorylate RSK-bound PDZ proteins. We have found 8 RSK1 
interaction partners that can be phosphorylated by ERK. One of them is ARHGEF12, which 
contains three RSK phosphorylation sites and a single MAPK phospho-site (Figure 5C). In these 
cases, the C-terminal tail of RSK appears to serve a scaffolding role, bringing ERK and PDZ 
substrates close to each other. 
 
To identify additional indirect, PDZ scaffold-mediated substrates, all potential interaction partners 
of our RSK1-binding PDZ scaffolds were collected from the IntAct PPI database [36]. This analysis 
revealed the significant enrichment of RSK and ERK substrates in many cases. For example, an 
interesting scaffold was MAGI1, which was not identified previously as a direct substrate of RSK 
(or ERK). MAGI1 has 74 potential interaction partners in that database; among which more than 
40% turn out to be potential RSK substrates. Similarly, 30% of MAGI1 potential interaction 
partners are potential ERK substrates, and 18% of them are potential substrates of both RSK and 
ERK (Figure 5D, Table S3). We have found similarly significant enrichment of RSK/ERK 
substrates among various interaction partners, such as ARHGEF11. In conclusion, while only a 
small portion of RSK1-binding PDZ proteins may be direct substrates of RSK1, it appears that 
many of them may act as scaffolds, since many relevant potential RSK and ERK substrates can be 
found among their interaction partners. 
 
Kinetic control of substrate phosphorylation 
 
Next, we measured the kinetic parameters of PDZ-PBM interactions (Figure S4). PDZ-bound 
fluorescent peptides were rapidly mixed with high molar excess of unlabeled peptides and changes 
in fluorescence polarization were monitored. Although the fluorescein label may alter the steady-
state affinity of some interactions (Table 1), it probably affects only the dissociation rates, as 
usually observed for large hydrophobic groups. Under this assumption, unbiased off-rates for 
unlabeled peptides can be estimated (Figure 6A). Our results revealed that OFF dimmers have a 
generally slow binding kinetics (average koff ≈ 210 s
-1
), while ON dimmers showed faster 
dissociation rates (average koff ≈ 1100 s
-1
 ) (Figure 6B). We used an in silico network-based 
modeling software to estimate substrate phosphorylation efficiency using these obtained kinetic 
parameters (Figure S5) [37]. By using this simulation the phosphorylated substrate levels, induced 
by the same amount of external stimulation, could be calculated and compared for ON and OFF 
switches (Figure 6C). The analysis demonstrated that the presumed weaker interaction between 
OFF-dimmer PDZ domains and the active kinase, should be compensated by a slower dissociation 
rate, thereby allowing higher substrate phosphorylation. 
 
Role of the RSK1 PBM in RhoA activation 
 
RSK proteins have been proposed to play an important role in regulating cell motility, particularly 
through affecting the activity of the small GTPase protein, RhoA [38] [21]. To this end, we have 
examined the role of the RSK1 C-terminal region in RhoA activation. We transiently transfected a 
RSK1/2 knockout HEK293T cell line with either full-length RSK1 (WT, 1-735) or a RSK1 
construct with its C-terminal residue truncated (ΔC1, 1-734). We have found that overexpressed 
and phosphorylated RSK1 localized in the cytoplasm, similarly to the endogenous phospho-RSK in 
wild type HEK293T cells (Figure 7A) [15]. Interestingly, an increased level of basal RhoA activity 
was only apparent in the presence of the WT RSK1 construct (Figure 7B). This slight increase was 
more pronounced in cells that were stimulated by the addition of serum. Stimulation increased 
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RhoA activity in the presence of the WT RSK1 construct, but not in the presence of RSK ΔC1 
(Figure 7C). These results are consistent with a model postulating that the PBM of RSK1 serves as 
a docking motif for RSK1 to phosphorylate an important regulatory site in ARHGEF12, which then 
affects RhoA activation (Figure S6) [39] [40]. 
 
DISCUSSION 
 
Regulation of RSK1-PDZ interactions by PBM autophosphorylation 
 
Previously, only a handful of PDZ interaction partners of RSK1 had been identified and their 
response to RSK1 autophosphorylation was largely unknown. Here, we characterized the PDZ 
interactome of RSK1 and examined how this changes upon PBM autophosphorylation at Ser732. 
Altogether, 34 interaction partners were identified with the holdup assay, most of them being novel, 
with the notable exception of MAGI1. In contrast to previous reports, we did not detect any 
interaction of RSK1 PBM with the first PDZ domain of NHERF (EBP50) and only detected a very 
weak affinity towards the first PDZ domain of Scribble (BI ≈ 0.17-0.18, corresponding to a 
dissociation constant of 60-70 μM) [25] [18]. We do not think that this may be due to a lack of 
activity of these two domains in our assay, since both of them have already been positive with other 
PBMs in other holdup experiments. In particular, Scribble is positive with HPV16 E6 (BI ≈0.70, 
corresponding to a dissociation constant of 5-10 μM) [19]. Although most of the identified 
interactions were altered by PBM phosphorylation to some degree, we have found only a few cases 
that can be considered a genuine “phospho-switch”. For example, detectable binding of RSK1 to 
ARHGEF12 and GRID2IP was mostly eliminated, while binding to the adapter protein SNX27 was 
promoted by phosphorylation. In contrast, most substrates showed a “phospho-dimmer” effect, 
where phosphorylation modulated binding rather than switching it ON or OFF. Approximately as 
much ON as OFF dimmers were identified. These partners are able to interact with both states of 
the RSK1 PBM, albeit with different affinities. The rest of the interaction partners (such as 
PARD3B) displayed comparable affinities to both states of the RSK1 PBM and therefore these 
interaction partners are likely unable to sense the presence or absence of the phosphoryl group. 
Similar dimming mechanism was described on phosphorylation of PDZ domains themselves [41]. 
 
Mitogenic stimulation, such as that mediated by EGF, activates the MAPK pathway. Eventually, the 
downstream signals will activate ERK, leading to RSK1 phosphorylation and subsequent 
autophosphorylation in Ser732 of its PBM. Therefore, upon stimulation, we can expect dynamic 
changes in the RSK PBM-PDZ interactome based on quantitative in vitro measurements. To test 
this assumption, we created five intracellular PPI sensors for selected PDZ-dependent RSK1 
interactions. In our assays, ARHGEF12, GOPC and MAGI1 showed a preference for the native 
PBM, while the PDZ domain of SYNJ2BP preferred the phosphorylated PBM. In contrast, 
PARD3B could interact with both versions of RSK1. This cell-based protein-protein interaction 
study showed that EGF stimulation induces a phosphorylation-mediated rewiring of the RSK1-PDZ 
interactome inside cells, following the trends of the in vitro observations. 
 
Further analysis on RSK and its PDZ-containing binding partners indicated that some of the latter 
are phosphorylated by RSK. Among the unambiguously identified RSK substrates, ARHGEF12 has 
a prominent place. It is a strong partner of the RSK1 peptide and their interaction is responsive to 
EGF stimulation. Moreover, Shi et al. have recently showed that the association between RSK2 and 
ARHGEF12 (also known as Leukemia-associated RhoGEF or LARG) is essential in RhoA 
activation in glioblastoma cells [21]. They discovered that RSK can interact with ARHGEF12 and 
phosphorylate it at Ser1288. They demonstrated that the presence of RSK is essential for the 
association between RhoA and ARHGEF12, and for subsequent RhoA activation. Inactivation or 
inhibition of RSK eliminated RhoA activation in response to extracellular stimulation. Our 
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experiments gave similar results with RSK1, highlighting the central role of the RSK PBM in this 
process (Figure 7 and Figure S6). 
 
Kinetic compensation in dynamic networks 
 
Many direct substrates or substrate-tethering scaffolds of RSK (e.g. ARHGEF12 or MAGI1) 
contain an OFF dimmer PDZ domain. This creates a paradoxical situation, because the active kinase 
will down-regulate complex formation, and thus only a smaller fraction of the kinase should be 
capable of mediating the phosphoryl transfer. Despite this, phosphorylation of such OFF dimmer 
type substrates can be detected with high confidence (e.g. Ser1288 of ARHGEF12). Here, we 
propose that the lifetime of these OFF dimmer interactions can substantially increase their 
phosphorylation. In our experiments, OFF dimmer PDZ domains showed 5 times slower 
dissociation rates than ON dimmer interactions (Figure 6 and Figure S4). This kinetic compensation 
can largely contribute to substrate phosphorylation (Figure S5). We should emphasize here that 
these are general principles and they should be true for many other feedback-coupled enzymatic 
processes [42]. 
 
Phosphorylation-sensitive PDZ domains 
 
Phosphorylation of PBMs is a very common regulatory mechanism in human cells [18]. Based on 
our experiments, we identified a set of PDZ domains that are responsible for mediating the OFF or 
ON dimmer effects of the phosphorylatable -3 position of the RSK PBM. Comparison of PDZ 
sequences reveals that there is no obvious driving force behind OFF dimmer behavior, but there are 
at least three positions within the peptide binding groove that can be important for ON dimmers 
(Figure 8). The first of them is the outward facing residue of the second strand (βB) of the PDZ 
domain. This side chain is positioned in close proximity of the phosphate group, and while it is 
usually a Ser/Thr residue in PDZ domains, an Asn residue is preferred within ON dimmers. The 
other two altered side chains are within the third strand (βC) of the PDZ domain. Here, both 
external side chains are altered in ON dimmers. Interestingly, the closest residue to the phosphosite 
is most frequently a Ser residue and the other one is a basic amino acid. The role of two of these 
residues in the coordination of the phosphate group was captured in a crystal structure of SNX27 
[43]. Asn56 from βB and Ser82 from βC mediate a hydrogen bond with the phosphate group of 
PBMs. Moreover, replacing the basic residue in the βC (Arg762) to Ala in Scribble can swap the 
RSK3 binding properties from ON- to OFF-dimmer [18]. These observations led us to the 
conclusion that ON dimmer propensity is determined by the presence of phosphate acceptor sites 
while OFF dimmer propensity is currently not understood. Further studies are needed to collect 
more evidence about such effects and classify PDZ domains on the basis of their response to 
phosphorylation events at different positions of their target PBM sequences. 
 
Response to phosphorylation: switches and dimmers 
 
Phosphorylation can alter linear motif binding by multiple ways. In the literature, most examples of 
phosphorylation-induced PPI changes are considered as switches (usually called “phospho- 
switches”), which can turn PPIs on or off. However, signaling processes are not solely based on 
binary events and may also involve fine-tuning mechanisms. A "switch" refers to binary transitions 
between two distinct states (the interaction occurs or does not occur), while a "dimmer" allows a 
fine tuning mechanism (smaller or larger changes in the affinity of an interaction). The dimming 
mechanism makes sense for describing events based on non-covalent interactions, however in some 
cases (e.g. in the context of additional binding events) synergism can enhance this effect resulting in 
switch-like changes. Our results demonstrate a continuum between ON and OFF switches, 
including many gradually altered dimmers, suggesting that, among phosphorylation-induced 
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changes, ON/OFF dimmer effects may predominate, while ON/OFF switches represent only 
extreme cases.  
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Table 1. Summary of the in vitro experiments. Values after the semicolon correspond to the 
phosphorylated RSK1 peptides. HPV16 E6 was used as an internal standard during the SPR 
measurements. Kd estimation was calculated from BI values as described in materials and methods 
and using an estimated 17 µM peptide concentration. Fold changes were calculated by dividing the 
estimated unphosphorylated and the phosphorylated dissociation constants. For undetectable 
interactions, a very weak Kd was assumed (100 µM, which corresponds to a BI of 0.14). ND means 
not determined, while no binding means that it was impossible to quantitatively measure their 
affinities in our experimental conditions. 
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Figure 1. The activation of RSK includes a feedback phosphorylation site that can affect PDZ 
binding. (A) Activation of the tandem kinase RSK is a multi-step process. Activation of RSK is 
initiated by ERK docking, which is followed by the phosphorylation of the C-terminal kinase 
domain (CTKD) [9]. The active CTKD phosphorylates a linker site between the kinase domains 
that creates a docking site for PDK1 [11]. In the end, PDK1 activates the N-terminal kinase domain 
(NTKD) [10]. Usually, only the NTKD is considered as an effector kinase and the CTKD is only 
associated with a self-regulatory role, but one of these activated kinases phosphorylates its C-
terminal PBM. While RSK is an effector of the mitogenic ERK pathway, its downstream effects are 
not well-explored. (B) Each RSK isoforms contain a functional class 1 PBM. RSK1 contains 3 
mutually exclusive autophosphorylation sites (at the -1,-2,-3 positions) and the other isoforms 
contain only two (at the -2, -3 positions), but only the -3 site (Ser732 in RSK1) is considered as a 
major feedback site [16]. The structural panel shows RSK1 binding to the second PDZ domain of 
MAGI1. 
 
Figure 2. PDZome binding of RSK1 explored by in vitro protein-peptide binding assays. (A) 
PDZome binding profiles of unphosphorylated and phosphorylated RSK1 PBMs. A red line 
indicates the cutoff for a significant PDZ-PBM interaction (BI>0.2). PDZ domains in the upper and 
lower plots are ranked on the basis of their BIs for the indicated peptide. In the middle plot, PDZ 
domains are ranked on the basis of their BIs for the unphosphorylated peptide, while the plotted BI 
values are those obtained for the phosphopeptide. Note the considerable reshuffling of binding 
ligands induced by phosphorylation. (B) Comparison of orthogonal binding data obtained by the 
holdup assay, SPR and a fluorescence polarization based assay (FP). The correlation of binding 
intensities (BI) obtained by holdup assays to the affinities deduced from SPR or competitive FP 
measurements were fitted using a Monte Carlo approach. Despite the independent affinity 
measurement procedures, a similar correlation was observed in both cases. The fitting procedure 
delivers a value for the peptide concentration in the holdup assay, combining this with the free and 
peptide-bound PDZ domain concentrations (both delivered by the holdup assay), the dissociation 
constant of all human PDZ domains could be determined. 
 
Figure 3. Binding affinity changes elicited by PBM phosphorylation. (A) Domain architecture 
of the identified interaction partners. The PDZ domains are colored according to the measured BI 
values. (B) Using lowered cutoffs in the holdup assay (Kd < 100 µM), almost half of the identified 
RSK1 interaction partners showed detectable affinity to both states of the RSK1 C-terminal peptide. 
(C) Phosphorylation promotes a complex rearrangement in the RSK1 PDZ interactome. Instead of 
two definite classes (ON or OFF switching), a continuum (ON or OFF dimming) was measured in 
the phosphorylation induced Kd differences of the holdup assay. Dark gray columns show the 
experimentally determined Kd differences from the competitive FP measurements. 
 
Figure 4. Live-cell monitoring of RSK1 binding to PDZ-containing partners. (A) Monitoring 
steady-state luminescence with the interaction sensors between RSK1 and full-length PDZ proteins. 
Full-length proteins fused to two complementary fragments of nanoluc luciferase were co-expressed 
in serum starved HEK293T cells. The resulting luminescence signal was measured as indicated in 
the materials and methods. The luminescence signal obtained for the pair of wild-type constructs is 
used as reference (relative luminescence). The L714E RSK1 mutant is known to eliminate the 
interaction between RSK1 and ERK [9]. The ΔC1 RSK1 mutant does not contain the last C-
terminal residue of RSK1 and therefore does not contain a functional PBM. The luminescence 
signal is consistently disrupted by the ΔC1 mutation, indicating that this signal reports on the PBM-
mediated binding of RSK1 to its PDZ-containing targets. The L714E mutation disrupts the signal in 
cases where the interaction partner can significantly interact with the phosphorylated form of RSK1. 
(n=6) Asterisks indicate statistical significance (*** P<0.001) calculated by two-tailed Student’s t-
test between the luminescence signals of mutant and WT RSK1 constructs. (B) RSK1 based 
luminescence interaction sensors (with ERK2 and several proteins containing RSK1-binding PDZ 
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domains) were co-expressed in serum-starved HEK293T cells. The luminescence signal in absence 
and in presence of EGF (20 ng/ml) was monitored for sixty minutes following EGF addition. The 
measured luminescence signal was normalized to the initial luminescence and to the spontaneous 
substrate (furimazine) decay based on the unstimulated cells. The dark and grey curves show the 
luminescence signals of the WT and the L714E mutant, respectively. EGF stimulation provokes a 
time-modulated decrease of the luminescence signal for co-expressed constructs of RSK1 and 
ERK2 as observed in our previous work [15]. Note that EGF stimulation diversely modulates the 
luminescence signal (increase, decrease or no significant change) for each PDZ-containing protein 
in a comparable timescale to that of RSK-ERK dissociation. Remarkably, in this cell based assay, 
using full length proteins, EGF-induced luminescence signal modulation shows a good agreement 
to the results of in vitro measurements where only an RSK1 PBM peptide and PDZ domains 
constructs were used. 
 
Figure 5. Meta-analysis of phosphoproteomic studies and bioinformatic search to find 
potential direct and indirect PDZ-dependent substrates of RSK and of ERK. (A) Left panel: a 
graphical representation of the intersections of RSK substrate lists from four different HTP 
phosphoproteomic studies: (i) Galan et al. [26], (ii) Moritz et al. [27] (iii) Avey et al. [28], (iv) 
[RK]xx[ST] subset of the ERK compendium [29]. Middle panel: the intersection of the four lists 
contains several previously characterized RSK substrates (underlined), suggesting that other 
proteins found in this group may also represent high-confidence RSK substrates. Right panel: the 
RSK compendium and the direct ERK compendium greatly overlap, suggesting that a set of 
substrates can be phosphorylated on both ERK ([ST]P) and RSK ([RK]xx[ST]) consensus sites. (B) 
Same representation as in (A) but focusing on RSK substrates with PDZ domains. Only a few PDZ 
domain-containing substrates are present in the whole dataset, and only a handful of them were 
found in more than one HTP study. Moreover, only four RSK1 binding partners were identified, 
from which only ARHGEF12 was found in the common group of the HTP studies. Uncharacterized 
PDZ partners may be direct partners of other RSK isoforms, or may be PDZ-independent substrates 
or false positives. (C) Many RSK1 PDZ interaction partners contain an ERK phosphorylation site. 
Additionally, a few substrates, such as ARHGEF12, can be phosphorylated by both kinases. (D) 
The IntAct database was used to estimate the enrichment of ERK and RSK substrates among the 
interaction partners of the RSK1 PDZ-dependent interaction partners. On the vulcano plot, each dot 
represents the enrichment of kinase substrates among the interaction partners of a PDZ scaffold. We 
have identified a high number of potential indirect RSK and ERK substrates among these 
interaction partners, which are indicated with colors in the upper right corner. P values indicate 
statistical significance compared to a random pool of intracellular proteins, calculated by Chi-
square test. Fold enrichment indicates the increased proportions of substrates compared to the same 
random pool. 
 
Figure 6. Binding kinetics differ between ON and OFF dimmers. (A) Dissociation rates were 
deduced from stopped flow fluorescence polarization experiments. On-rates are calculated based on 
the steady state affinities of the fluorescent peptides (deduced from direct FP measurements). The 
bias factor (the ratio of the binding affinities of the direct FP and the holdup assay) was applied as a 
correction factor to the fitted dissociation rates to estimate unbiased off-rates. Values after the 
semicolon correspond to the phosphorylated RSK1 peptides. ND means not determined. (B) The 
corrected dissociation rates (koff*) of a set of RSK1-PDZ interactions. Partners with OFF dimmer 
behavior showed a slower binding kinetics while ON dimmers preferred faster binding rates. (C) 
Substrate phosphorylation was calculated using an in silico model with measured dissociation rates.  
 
Figure 7. The PBM of RSK1 links ERK activation to RhoA. (A) A RSK1/2 knockout HEK293T 
cell line was used to measure the role of the PBM of RSK1 in a native environment. Deletion of the 
RSK1 PBM does not affect the localization of active RSK1. (B) The presence of intact RSK1 
increases the basal RhoA activity but this effect is decreased without a functional PBM. (n=4) (C) 
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Transfected and serum-starved cells were stimulated with serum (20% for 5 min). Without intact 
RSK1 (in the mock transfected knockout cell or in the presence of the PBM-lacking RSK1 
construct), only minor increment was observed in the RhoA activity. The presence of intact, wild 
type RSK1 enabled a proper response in RhoA activation upon stimulation. (n=4) Asterisks indicate 
statistical significance (** P<0.005, * P<0.01, NS P>0.01) calculated by two-tailed Student’s t-test. 
 
Figure 8. Determinants of -3 phospho-PBM specificity. The PBM binding groove of ON dimmer 
PDZ domains display some notable sequence preferences. Sequence logos were generated from 
every human PDZ sequences or from identified dimmer subsets of the RSK1 peptide partners. 
Important differences are underlined in the ON dimmer sequence logo and their side-chains are 
showed with sticks in the structure of the OFF dimmer MAGI1. In contrast to ON dimmers, no 
preferences was identified for OFF dimmers.  
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Supplement 
 
Figure S1. Raw results of the HU assay measured by the caliper. The overlay of processed 
electropherograms between the biotin control and the peptide experiment is shown for the most 
significant interaction partners of RSK1. The average BI value is highlighted in each panel. The 
more depleted the PDZ peak in the peptide experiment, the stronger is the binding of the PDZ 
domain to the peptide. 
 
Figure S2. Results of the SPR measurements. The four channel of the CM5 chip was split into a 
negative control, a HPV16E6 internal control (green), an unphosphorylated (black) and a 
phosphorylated (red) surface, and the significant RSK1 interaction PDZ domains (fused to MBP) 
were injected onto the surface. Only steady state analysis was performed due to biphasic 
sensograms. 
 
Figure S3. In solution measurements of RSK-PDZ interactions. (A) Fluorescence polarization 
measurements were carried out to measure the binding of multiple PDZ domains. Direct binding 
means measurement with a fluorescein labeled 7 residue long RSK1 peptide, while competitive 
measurements were measured with a 40 residue long native or monophosphorylated peptide 
(colored black and red, respectively). (B) ITC binding experiments were performed between the 
RSK1 and the PDZ domains of the strongest interaction partners of each peptides (of ARHGEF12 
and SYNJ2BP) at 37°C. The calorimetric measurements confirmed the differential binding upon 
phosphorylation. 
 
Figure S4. Summary of the stopped flow measurements. (A) The PDZ-complexed fluorescent 
RSK1 peptide was mixed with high amount of unlabeled peptide. The change in the fluorescence 
polarization was monitored during the dissociation phase. (B) Measured off-rates of the labeled 
peptides. (C) Substrate phosphorylation was in silico estimated using their measured dissociation 
rate. 
 
Figure S5. In silico modeling of PDZ substrate phosphorylation by RSK1. (A) This simplified 
mathematical model was used to simulate MAPK pathway activation. (B) Network based 
simulation shows that only a small fraction of activated RSK1 has an unphosphorylated PBM (even 
in the presence of high amount of PDZ domain). (C) Interaction partners with negative feedbacks 
show dissociation upon stimulation. While the dissociation profile is off-rate dependent, the 
substrate phosphorylation rate is not. The system shows an optimal substrate phosphorylation at a 
low dissociation rate. (D) In contrast to the OFF dimmers, substrates with a positive feedback show 
an association profile. Increasing their dissociation kinetics increases their substrate 
phosphorylation rate. Note that the dynamics of the interactions are very similar to the results of our 
cell-based measurements, but we do not have any periodicity in this isotropic system. (E) A set of 
RSK substrates were in silico phosphorylated using an artificially slow or fast dissociation rate. 
Partners showing an OFF dimmer behavior preferred a slower binding kinetics, while ON dimmers 
preferred faster kinetics. 
Figure S6. The RSK phosphorylation site is adjacent to an ARHGEF12 regulatory site with 
currently unknown function. (A) The activity of ARHGEF12 can be controlled via the MAPK 
pathway. Inhibition of the MAPK pathway alters the level of GTP bound RhoA. To visualize this 
effect, we overexpressed WT ARHGEF12 in HEK293T cells, which resulted in a significant 
increase in the basal level of active RhoA. MEK inhibition decreased, while RSK inhibition 
increased active RhoA levels. (n=4) (B) Mimicking the RSK1 phosphorylation site on ARHGEF12 
(S1288E) or introducing a RhoA binding incompetent mutant (W769D) affected RhoA activation 
[40]. Phosphomimicking mutation decreased the signal by 20% and the W769D mutation by 50%. 
(n=4) The schematic model of ARHGEF12/LARG activation is highlighted on the right side, 
including GAP and GEF activities. (C) Stimulation, phosphomimicking mutation or RSK/MEK 
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inhibition did not affect the intracellular localization of the mCherry fused ARHGEF12 in 
HEK293T cells [39]. 
 
 
 
Table S1. Results of the HU assay. (BI values for both peptide.) 
Table S2. The RSK substrate compendium. 
Table S3. PDZ-scaffold mediated complexes. 
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Materials and methods 
 
Holdup assay The automated holdup assay was carried out against peptides (RSK1725–735) in 
triplicates as previously described [19] with minor modifications. In brief, we measured the fraction 
of PDZ depletion (BI) in the fluid phase during a pull-down experiment. For the detailed protocol 
please look at [20]. The sequences of the clones of the PDZome v2 were designed according to [2]. 
All genes were codon optimized for E. coli expression and cloned into a pETG41A plasmid. All 
protein constructs were expressed in Escherichia coli following the previous protocol [19] with 
minimal modifications. All constructs were checked for solubility and cell lysate soluble fractions 
were adjusted to approximately 4 µM concentration and frozen in 96 well plates. Additionally, mass 
spectrometry was used to confirm the identity of each PDZ clones. For the detailed protocols of 
production and quality control, please look at [20]. We measured interactions against 255 proteins 
with the unphosphorylated peptide and against 252 proteins with the phosphorylated peptide. The 
missing proteins from the human PDZome (consisting of 266 proteins) showed problems with the 
expressions or stability of these constructs, or we had technical issues during the assay. In this 
work, BI = 0.2 was used as the minimal BI threshold value to define high-confidence PDZ-PBM 
pairs, as proposed previously [19]. Figure S1 contains the BI values of the RSK1 and phospho-
RSK1 datasets. Data were analyzed as formerly described [19]. All plots and calculations in this 
work were done using these conventional datasets. Additionally, we already provide the values 
calculated with an updated protocol in the supplemental file, because the new calculation approach 
will set the standard for future holdup papers. These were generated using an automated 
computational protocol awaiting for publication. This updated analysis revealed three new 
interaction partners of the native RSK1 peptide (SCRIB-3, MPDZ-10 and RHPN1) and four new 
partners of the phosphorylated peptide (SCRIB-3, LI 7A, PDZRN3-2 and DLG3). Apart from 
these weak interaction partners, most values are coherent between calculations. 
 
Protein expression and purification and peptide synthesis Tandem affinity (Ni- and MBP-) 
purified MBP-PDZ proteins were used in biochemical assays. Unphosphorylated RSK1683–735 
peptides were recombinantly expressed with an N-terminal cleavable GST tag. After affinity 
purification, the GST tag was removed and the peptide was isolated by reverse phase HPLC. A 
fraction of the isolated peptide was phosphorylated with a constitutively active (T573E mutant) 
RSK1 C-terminal kinase domain as formerly described [19]. Unphosphorylated, phosphorylated, 
fluorescein labeled or unlabeled RSK1729–735 peptides were all chemically synthesized on an 
automated PSE Peptide Synthesizer (Protein Technologies, Tucson, AZ, USA) with Fmoc strategy. 
Biotinylated RSK1725-735 peptides were purchased from JPT Innovative Peptide Solutions with 70-
80% purity. The biotin group was attached to the N-terminal via a TTDS linker. Protein (and Tyr 
containing peptide) concentrations were determined by UV spectroscopy. For peptides that lacked 
an aromatic residue, their dry mass was directly measured. Predicted peptide masses were 
confirmed by mass spectrometry. 
 
Isothermal titration calorimetry (ITC) ITC measurements were carried out in 20 mM Hepes pH 
7.5, 150 mM NaCl, 500 µM TCEP using a VP-ITC apparatus (MicroCal). 50 µM MBP-PDZ 
domain was titrated with concentrated peptides at 37 °C. The Origin for ITC 5.0 (Originlab) 
software package was used for data processing. 
 
Surface plasmon resonance (SPR) SPR measurements were performed on a Biacore T200 
instrument equipped with CM5 sensor chip. Streptavidine was immobilized on the sensor chip with 
EDC-MS using a standard protocol. Biotinylated peptides (RSK1, pRSK1, HPV16E6) were 
immobilized on streptavidine and after an extensive washing step, MBP-PDZ domains were 
injected onto the chip at 8 different concentrations and with two additional replicates. 
Unfortunately, our SPR analysis did not reveal the kinetic parameters of the studied PDZ-peptide 
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interactions due to biphasic and very fast behavior. The saturated phase of the reference channel 
subtracted data was fitted with a hyperbolic function. 
 
Steady state fluorescence polarization Fluorescence polarization was measured in 384-well plates 
(Corning) using Synergy H4 multi-mode reader (BioTek). For direct titration experiments, 50 nM 
reporter peptide (RSK1729-735) was mixed with increasing amount of MBP-PDZ domains. In 
competitive measurements, the 50 nM reporter peptide was mixed with the PDZ domain in a 
concentration to achieve high degree of complex formation. Subsequently, increasing amount of 
unlabeled peptide (RSK1683-735) was added to the reaction mixture. Titration experiments were 
carried out in triplicate and the average FP signal was used for fitting the data to a quadratic or 
competitive binding equation. 
 
Monte Carlo modeling To estimate the dissociation constant of weak interactions, we used the 
measured BI values from the HU assay. This parameter equals the bound fraction of the PDZ 
domain, therefore, it can be inserted directly into the general binding equation: 
𝐾𝑑 =
[𝑃𝐷𝑍𝑓𝑟𝑒𝑒] ∗ [𝑅𝑆𝐾𝑓𝑟𝑒𝑒]
[𝑃𝐷𝑍 − 𝑅𝑆𝐾𝑐𝑜𝑚𝑝𝑙𝑒𝑥]
=
([𝑃𝐷𝑍𝑡𝑜𝑡] − 𝐵𝐼 ∗ [𝑃𝐷𝑍𝑡𝑜𝑡]) ∗ ([𝑅𝑆𝐾𝑡𝑜𝑡] − 𝐵𝐼 ∗ [𝑃𝐷𝑍𝑡𝑜𝑡])
𝐵𝐼 ∗ [𝑃𝐷𝑍𝑡𝑜𝑡]
 
Assuming that the total PDZ domain concentration is ~ 4 µM, the only unknown parameter is the 
total peptide concentration. Instead of a simple nonlinear fit, we have used an in-house Python 
script for Monte Carlo modeling and least squares fitting to utilize the standard deviations of the 
HU assay and the Kd measurements. Each fitting was repeated 10000 times and the average peptide 
concentration along with the lower and upper quartiles were plotted in figure 2B. Based on our SPR 
measurements, the RSK peptide concentration should be around 20 µM (most probably between 18-
21 µM). Direct FP indicates that this concentration should be around 14 µM (most probably 
between 6-20 µM). In the case of the competitive FP, we have found that the peptide concentration 
should be around 14 µM (most probably between 9-18 µM). For Kd extrapolation, we have used a 
peptide concentration of 17 µM. 
 
Protein-protein interaction assay The NanoBiT PPI MCS starter system was purchased from 
Promega. The N-terminus of RSK1 was tagged with the short NanoBiT tag (SmBiT) and either the 
N- or the C-terminus of the interaction partner with the large NanoBiT tag (LgBiT). Full-length 
RSK1 was cloned into pBit2.1-N[TK/SmBiT] vector. Full-length MAGI1 and ERK2 constructs 
were previously cloned into the LgBiT vector. Full-length ARHGEF12 (isoform 2), GOPC (isoform 
2), PARD3B (1-913) and SYNJ2BP were cloned into the pBit1.1-N[TK/LgBiT] vectors. All 
constructs were cloned from HEK293T or HeLa cDNA pools and were confirmed by sequencing. 
HEK293T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Lonza) containing 
10% fetal bovine serum and 1% penicillin/streptomycin/amphotericin B. 2x10
4
 cells/well were 
seeded onto a white, TC treated 96-well plate (Greiner) 24 hours prior to transfection. Transient 
transfections were carried out with FuGene HD reagent (Promega) according to the NanoBiT 
system's instructions. 4 hours after transfection, cells were starved for 20 hours in CO2-independent 
medium (Thermo). Cells were assayed 24 hours after transfection using Nano-Glo reagent 
(Promega) and a Synergy H4 plate reader (BioTek). Experiments were carried out according to the 
manufacturer's instructions. To validate the interaction sensors, we compared the steady-state 
luminescence signals of different mutants in serum-starved cells. Stimulation was performed using 
20 ng/ml EGF (Sigma-Aldrich). Each experiment was performed with at least 6 biological 
replicates. We must note that we observed that the observed periodicity in the luminescence 
appeared environment dependent, as even under slightly modified conditions (i.e. different media,  
cell density or protein expression level) no periodic features appeared. 
 
Signaling pathway modeling Rule based network modeling was carried out with the software 
package BioNetGen with the ordinary differential equation solver running on a desktop PC. The 
simulated pathway was described in figure S5A. Pathway activation was initiated from a pre-
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equilibrated state. The simulation was initiated by introducing the “Stim” to the system. This 
simplified, artificial signal generator was adjusted to mimic the natural activation profile of the 
ERK pathway upon EGF stimulation. 
 
Stopped-flow fluorescence polarization Fast kinetic measurements were performed with the 
stopped-flow instrument SFM-300 (Bio-Logic) with polarized excitation at 488 nm. Parallel and 
perpendicular fluorescent emissions were measured through a 550 +/- 20 nm band pass filter 
(Comar Optics). All reactions were measured at 25 °C in a buffer containing 20 nM Hepes pH 7.5, 
150 mM NaCl, 150 µM TCEP. Post-mixing fluorescent peptide concentration was 0.5 µM. The 
fluorescent peptide (RSK1729-735) was pre-complexed with high amount of MBP-PDZ domain (5-40 
µM, post-mix). To measure the dissociation of the labeled peptide, we rapidly mixed the PDZ 
bound complex with high molar excess of unlabeled peptide (RSK1729-735 100 µM, post-mix). Each 
experiment was carried out multiple times (n>9) and the averaged transients were fitted using a 
single exponential function. Corrections were applied to estimate the unbiased binding of an 
unlabeled peptide based on the dissociation constant differences between the direct FP 
measurements and the unbiased HU assay. 
 
Immunofluorescence For detection of the intracellular localization of transfected proteins 1x10
5
 
cells/well were seeded onto a cover slip-containing (Assistent) 24-well plate. Cells were fixed with 
4% PFA solution and blocked for 1 hour in 5% BSA and 0.3% Triton-X 100, dissolved in PBS at 
room temperature. The RSK1/2 knockout (CRISPR) HEK293 cell line was a kind gift from Fanxiu 
Zhu. To introduce exogeneous WT or mutant RSK1 into these cell lines, we created pIRES2-EGFP 
based vectors, which expressed untagged RSK1s along with a GFP transfection reporter gene. 
Phosphorylated RSK was detected with the help of anti-pRSK pSer380 (1:800, CST) primary and 
Alexa Fluor 647 (anti-rabbit, 1:800, Thermo) conjugated secondary antibodies. ARHGEF12 
(isoform 2) was cloned into a pmCherry-C1 vector. Mutations were introduced by QuickChange 
site-directed mutagenesis. Nuclear staining was performed using DAPI (0.1 μg/ml). After washing, 
cover glasses were mounted to microscopy slides by Mowiol 4-88 mounting medium (Sigma-
Aldrich). Confocal microscopy was carried out using a Zeiss LSM 710 system (Carl Zeiss 
Microscopy GmbH, Jena, Germany) with a 40X oil objective. Images were processed by the ImageJ 
software. 
 
RhoA activation assay The commercially available luminescence based G-LISA RhoA activation 
assay (Cytoskeleton) was used to measure the GTP bound RhoA levels in cell cultures. 2x10
5
 
cells/well were seeded onto a 24-well plate. G-LISA assay was performed according to the 
manufacturer’s recommendations, 24 hours after transfection with the exception of the 
concentration and the antibody dilutions. Sample concentrations were equalized to 1 mg/ml. 
Primary and secondary antibodies were diluted to 1:500 and 1:1000, respectively. Luminescence 
signal was detected on a Synergy H4 plate reader (BioTek). The RSK inhibitor BI-D1870 treatment 
was performed at 100 nM for 1h. The MEK inhibitor CI1040 was incubated ON at 100 nM. 
Inhibitor treatments were performed in Dulbecco’s Modified Eagle Medium supplemented with 
10% fetal bovine serum. Serum stimulation (20%) was performed with serum-starved cells for 5 
min.  
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BI KD, direct FP (µM) KD, competitive FP (µM) KD, SPR (µM) KD, SPR, HPV16 E6 (µM) KD, estimated (µM) Fold change
ARHGEF12 0.77 ± 0.02; 0.05 ± 0.05 7.5 ± 0.8; 29 ± 8 6.6 ± 1.7; >100 2.79 ± 0.11; no binding 10.9 ± 1.4 4.2; >100 0,04
GRID2IP-2 0.67 ± 0.02; 0.00 ± 0.01 5.1 ± 0.4; 47 ± 15 1.7 ± 0.3; 85 ± 11 3.96 ± 0.12; no binding no binding 7.1; >100 0,07
MAST2 0.74 ± 0.03; 0.23 ± 0.03 7.9 ± 0.6; 13 ± 2 19 ± 7; 48 ± 84 7.02 ± 0.27; no binding 2.5 ± 0.2 4.9; 53.8 0,09
PDZD7-3 0.60 ±0.03; 0.15 ± 0.03 0.80 ± 0.05; 1.8 ± 0.1 4 ± 1; 46 ± 7 6.2 ± 0.9; no binding no binding 9.7; 92.9 0,10
MAST1 0.57 ± 0.01; 0.08 ± 0.03 26 ± 4; 34 ± 8 5 ± 1; 92 ± 12 20 ± 1; no binding no binding 11.1; >100 0,11
GOPC 0.63 ± 0.05; 0.25 ± 0.10 20 ± 1; >100 27 ± 2; >100 8.92 ± 0.44; no binding no binding 8.5; 48.0 0,18
MAGI1-2 0.43 ± 0.02; 0.15 ± 0.02 ND; ND ND; ND no binding, no binding 3.4 ± 0.8 20.3; 92.9 0,22
NHERF3-1 0.41 ± 0.01; 0.03 ± 0.01 80 ± 20; 220 ± 30 ND; ND no binding, no binding 23 ± 3 22.1; >100 0,22
GORASP2 0.41 ± 0.02; 0.19 ± 0.01 67 ± 33; 114 ± 35 ND; ND no binding, no binding no binding 22.1; 69.2 0,32
GRASP 0.29 ± 0.01; 0.04 ± 0.01 ND; ND ND; ND ND; ND ND 38.8; >100 0,38
PARD3B-1 0.52 ± 0.05; 0.31 ± 0.02 27 ± 3; 6.8 ± 0.5 45 ± 7; 31 ± 3.5 4.0 ± 0.3; 6.1 ± 0.4 no binding 13.8; 35.1 0,39
MAGI2-2 0.42 ± 0.01; 0.23 ± 0.03 420 ± 30; 430 ± 45 ND; ND no binding, no binding 2.9 ± 0.14 21.2; 53.8 0,39
ARHGEF11 0.28 ± 0.06; 0.01 ± 0.02 ND; ND ND; ND ND; ND ND 40.8; >100 0,40
SHANK3 0.27 ± 0.03; 0.07 ± 0.01 ND; ND ND; ND ND; ND ND 43.0; >100 0,43
DFNB31-3 0.23 ± 0.04; -0.01 ± 0.02 ND; ND ND; ND ND; ND ND 53.8; >100 0,53
NHERF2-2 0.20 ± 0.04; 0.07 ± 0.05 ND; ND ND; ND ND; ND ND 64.8; >100 0,64
HTRA1 0.44 ± 0.03; 0.36 ± 0.01 30 ± 2; 11.3 ± 0.4 19 ± 3; 33 ± 2 no binding, no binding no binding 19.4; 27.7 0,70
MAGI3-2 0.28 ± 0.03; 0.28 ± 0.06 ND; ND ND; ND ND; ND ND 40.8; 40.8 1,00
PDZRN4-1 0.51 ± 0.02; 0.54 ± 0.03 33 ± 5; 14 ± 2 ND; ND 0.97 ± 0.18; 7.1 ± 0.9 6.0 ± 1.5 14.4; 12.6 1,14
SNTG2 0.41 ± 0.02; 0.52 ± 0.05 65 ± 2; 24 ± 2 24 ± 12; 4.8 ± 1.7 no binding; 37 ± 5 no binding 22.1; 13.8 1,60
PTPN3 0.05 ± 0.02; 0.21 ± 0.02 ND; ND ND; ND ND; ND ND >100; 60.8 1,66
SHROOM2 0.00 ± 0.01; 0.21 ± 0.01 ND; ND ND; ND ND; ND ND >100; 60.8 1,66
LIMK2 0.01 ± 0.06; 0.22 ± 0.07 ND; ND ND; ND ND; ND ND >100; 57.2 1,77
GORASP1 0.01 ± 0.02; 0.23 ± 0.03 ND; ND ND; ND ND; ND ND >100; 53.8 1,88
GRID2IP-1 0.06 ± 0.02; 0.24 ± 0.01 ND; ND ND; ND ND; ND ND >100; 50.8 1,99
LNX1-3 0.04 ± 0.02; 0.24 ± 0.07 ND; ND ND; ND ND; ND ND >100; 50.8 1,99
DLG4-2 0.11 ± 0.03; 0.25 ± 0.02 ND; ND ND; ND ND; ND ND >100; 48.0 2,10
PDZRN3-1 0.26 ± 0.01; 0.45 ± 0.01 90 ± 25; 17.5 ± 1.4 >100; 80 ± 10 no binding, no binding 8.6 ± 1.6 45.4; 18.6 2,45
LAP2 -0.02 ± 0.05; 0.28 ± 0.01 ND; ND ND; ND ND; ND ND >100; 40.8 2,47
SNTA1 0.31 ± 0.04; 0.53 ± 0.01 41 ± 11; 4.9 ± 0.4 81 ± 17; 10.5 ± 2.6 no binding; 90 ± 4 101 ± 40 35.1; 13.2 2,66
SNTB1 0.22 ± 0.04; 0.45 ± 0.08 18 ± 2; 1.5 ± 0.1 37 ± 6; 4.5 ± 0.3 no binding; 48 ± 5 27 ± 4 57.2; 18.6 3,08
PPP1R9A 0.00 ± 0.02; 0.33 ± 0.02 ND; ND ND; ND ND; ND ND >100; 31.8 3,17
SYNJ2BP 0.26 ± 0.07; 0.54 ± 0.03 39 ± 2; 16 ± 1 >100; 7 ± 1 no binding; 25 ± 1 33 ± 4 45.4; 12.6 3,59
SNX27 0.08 ± 0.07; 0.47 ± 0.02 25 ± 6; 4.4 ± 0.4 185 ± 25; 32 ± 5 no binding; 46 ± 9 no binding >100; 17.1 5,92
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Highlights 
 RSK-PDZ interactions are regulated by phosphorylation 
• RSK can recognize at least 34 PDZ domains in the human proteome 
• PDZ-mediated interactions are crucial in substrate targeting 
• Growth factor-induced RSK phosphorylation modulates the affinity of these interactions 
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